ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0004967

acute lymphoblastic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. acute lymphoblastic leukemia. Diseases, record MONDO_0004967. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004967

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
acute lymphoblastic leukemia
Open Targets
Open Targets ID
MONDO_0004967
Open Targets
Other names
ALL, ALL - acute lymphocytic leukaemia, ALL - acute lymphocytic leukemia, acute lymphoblastic leukaemia (ALL), acute lymphoblastic leukaemia (disease), acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (disease), acute lymphoblastic leukemia/lymphoma, acute lymphocytic leukaemia, acute lymphocytic leukemia, acute lymphocytic leukemias, acute lymphogenous leukaemia, acute lymphogenous leukemia, acute lymphoid leukaemia, acute lymphoid leukemia, leukemia, lymphoblastic, malignant, lymphoblastic leukemia, acute, precursor Lymphoblasic leukaemia, precursor Lymphoblasic leukemia, precursor cell lymphoblastic leukaemia, precursor cell lymphoblastic leukemia, precursor lymphoblastic leukaemia, precursor lymphoblastic leukemia
Open Targets
Disease Ontology
DOID:9952
Disease Ontology
NCI Thesaurus
C3167
NCI Thesaurus
Orphanet
ORPHA:513
Orphanet
Highest stage of its drugs
Approval, for 17 of its 306 drugs, from ClinicalTrials.gov, DailyMed, FDA, PMDA and TTD
Open Targets

Drugs306

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
CYTARABINECHEMBL803Small moleculeApprovalDailyMed227216211Drugs and targets
METHOTREXATECHEMBL34259Small moleculeApprovalDailyMed199195194Drugs and targets
BLINATUMOMABCHEMBL1742992AntibodyApprovalDailyMed125124124Drugs and targets
MERCAPTOPURINECHEMBL1200751Small moleculeApprovalDailyMed and TTD130122105Drugs and targets
PEGASPARGASECHEMBL2108546EnzymeApprovalDailyMed and PMDA696765Drugs and targets
DASATINIB ANHYDROUSCHEMBL1421Small moleculeApprovalDailyMed575555Drugs and targets
RITUXIMABCHEMBL1201576AntibodyApprovalDailyMed535252Drugs and targets
THIOGUANINECHEMBL727Small moleculeApprovalTTD464543Drugs and targets
INOTUZUMAB OZOGAMICINCHEMBL2108611Antibody drug conjugateApprovalDailyMed, PMDA and TTD464343Drugs and targets
CLOFARABINECHEMBL1750Small moleculeApprovalDailyMed and PMDA393737Drugs and targets

1 to 10 of 306

See all 306 drugs

Targets326

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ABL1Bcr/Abl fusion protein15Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitorApprovalhttps://conductscience.org/library/genes/25Drugs and targets
NR3C1Glucocorticoid receptor15Glucocorticoid receptor agonistPhase 3https://conductscience.org/library/genes/2908Drugs and targets
TOP2ADNA topoisomerase 2-alpha13DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitorPhase 3https://conductscience.org/library/genes/7153Drugs and targets
BCRBcr/Abl fusion protein11Bcr/Abl fusion protein inhibitorApprovalhttps://conductscience.org/library/genes/613Drugs and targets
FLT3Receptor-type tyrosine-protein kinase FLT311Tyrosine-protein kinase receptor FLT3 inhibitorPhase 3https://conductscience.org/library/genes/2322Drugs and targets
KITMast/stem cell growth factor receptor Kit10Stem cell growth factor receptor inhibitorApprovalhttps://conductscience.org/library/genes/3815Drugs and targets
CD19B-lymphocyte antigen CD199B-lymphocyte antigen CD19 binding agent; B-lymphocyte antigen CD19 cross-linking agentApprovalhttps://conductscience.org/library/genes/930Drugs and targets
PDGFRBPlatelet-derived growth factor receptor9Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitorApprovalhttps://conductscience.org/library/genes/5159Drugs and targets
CD22B-cell receptor CD227B-cell receptor CD22 binding agent; CD22 binding agent; CD22 inhibitorApprovalhttps://conductscience.org/library/genes/933Drugs and targets
TUBBTubulin7Tubulin beta inhibitor; Tubulin inhibitorPhase 3https://conductscience.org/library/genes/203068Drugs and targets

1 to 10 of 326

See all 326 targets

Trials951

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 36 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01190930Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPhase 39,3502020-06-23
Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE SULFATEIts record names the diseaseClinicalTrials.gov
NCT02883049Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPhase 35,9492024-03-12B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
CLOFARABINE, CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DAUNORUBICIN HYDROCHLORIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, HYDROCORTISONE SODIUM SUCCINATE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE SULFATE
Its record names the diseaseClinicalTrials.gov
NCT00103285Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhase 35,3772018-07-11Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic LeukemiaCYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINEIts record names the diseaseClinicalTrials.gov
NCT00075725
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase 33,1542015-08-06Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic LeukemiaCYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN HYDROCHLORIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINEIts record names the diseaseClinicalTrials.gov
NCT00408005Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaPhase 31,8952019-06-20T Acute Lymphoblastic Leukemia, T Lymphoblastic LymphomaASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN HYDROCHLORIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PREDNISONE, THIOGUANINE, VINCRISTINE SULFATEIts record names the diseaseClinicalTrials.gov
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic LymphomaPhase 38472022-02-23
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
BORTEZOMIB, VINCRISTINE SULFATEIts record names the diseaseClinicalTrials.gov
NCT0040094605-001: Treatment of Acute Lymphoblastic Leukemia in ChildrenPhase 38002017-06-14Drug/Agent Toxicity by Tissue/Organ, LeukemiaASPARAGINASE, IMATINIB, PEGASPARGASEIts record names the diseaseClinicalTrials.gov
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaPhase 36692022-12-06Recurrent B Acute Lymphoblastic Leukemia
ASPARAGINASE, BLINATUMOMAB, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, MITOXANTRONE HYDROCHLORIDE, PEGASPARGASE, THIOGUANINE, VINCRISTINE SULFATE
Its record names the diseaseClinicalTrials.gov
NCT00123487Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CMLPhase 36382014-10-22Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-PositiveDASATINIB ANHYDROUSIts record names the diseaseClinicalTrials.gov
NCT00549848Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaPhase 36002022-02-10Acute Lymphoblastic LeukemiaCLOFARABINE, CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINEIts record names the diseaseClinicalTrials.gov

1 to 10 of 951

See all 951 trials

Comparisons in its trials109

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29)4,378 of 4,609258 of 3624,971NCT00103285Trial comparisons
Dasatinib 140 mg QD vs Dasatinib 70 mg BID: serious adverse events228 of 304236 of 305609NCT00123487Trial comparisons
CML-CP With Prior Imatinib Only vs CML-AP With Prior Imatinib Only: Participants With (MMR) Major Molecular Response (Phase II)106 of 29918 of 122421NCT00109707Trial comparisons
Blinatumomab vs Standard of Care Chemotherapy: serious adverse events165 of 26749 of 109376NCT02013167Trial comparisons
Inotuzumab Ozogamicin vs Defined Investigator's Choice of Chemotherapy: serious adverse events85 of 16472 of 143307NCT01564784Trial comparisons
High Risk Patients vs Standard Risk Patients: Acute Graft-Versus-Host Disease2 of 1379 of 292305NCT00303719Trial comparisons
High Risk Patients vs Standard Risk Patients: Serious Adverse Events0 of 1347 of 292305NCT00303719Trial comparisons
High Risk Patients vs Standard Risk Patients: Overall Survival8 of 13181 of 292305NCT00303719Trial comparisons
High Risk Patients vs Standard Risk Patients: Transplant Related Mortality2 of 1340 of 292305NCT00303719Trial comparisons
High Risk Patients vs Standard Risk Patients: deaths from any cause6 of 13124 of 292305NCT00303719Trial comparisons

1 to 10 of 109

See all 109 comparisons in its trials

Papers from its trials646

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
39692275RESULT1PubMed
39418626RESULT1PubMed
39415930RESULT1PubMed
39218935RESULT1PubMed
37141547RESULT1PubMed
36108304RESULT1PubMed
34228505RESULT1PubMed
34097852RESULT1PubMed
33827116RESULT1PubMed
33593877RESULT1PubMed

1 to 10 of 646

See all 646 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004967

GET https://conductscience.org/api/diseases/v1/MONDO_0004967/drugs?page=2

API referenceFor AI assistants